Ovid Therapeutics (OVID)

Data from SEC filings
Employee count
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
Ovid Therapeutics Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on June 10, 2021. The results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2021.
Proposal 1: The Company’s stockholders elected the nominee as director to serve a three-year term until the 2024 Annual Meeting, or until her respective successor is duly elected and qualified, by the votes set forth in the table below:

NomineeForWithheldBroker Non-Votes
Barbara Duncan 27,065,759 6,894,669 19,036,051

Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2021 by the votes set forth in the table below: